215 related articles for article (PubMed ID: 35691495)
1. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Hiatt JB; Sandborg H; Garrison SM; Arnold HU; Liao SY; Norton JP; Friesen TJ; Wu F; Sutherland KD; Rienhoff HY; Martins R; Houghton AM; Srivastava S; MacPherson D
Clin Cancer Res; 2022 Oct; 28(20):4551-4564. PubMed ID: 35920742
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
4. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
5. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
[TBL] [Abstract][Full Text] [Related]
6. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation.
Rudin CM; Balli D; Lai WV; Richards AL; Nguyen E; Egger JV; Choudhury NJ; Sen T; Chow A; Poirier JT; Geese WJ; Hellmann MD; Forslund A
J Thorac Oncol; 2023 Sep; 18(9):1222-1232. PubMed ID: 37210008
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity.
Mahadevan NR; Knelson EH; Wolff JO; Vajdi A; Saigí M; Campisi M; Hong D; Thai TC; Piel B; Han S; Reinhold BB; Duke-Cohan JS; Poitras MJ; Taus LJ; Lizotte PH; Portell A; Quadros V; Santucci AD; Murayama T; Cañadas I; Kitajima S; Akitsu A; Fridrikh M; Watanabe H; Reardon B; Gokhale PC; Paweletz CP; Awad MM; Van Allen EM; Lako A; Wang XT; Chen B; Hong F; Sholl LM; Tolstorukov MY; Pfaff K; Jänne PA; Gjini E; Edwards R; Rodig S; Reinherz EL; Oser MG; Barbie DA
Cancer Discov; 2021 Aug; 11(8):1952-1969. PubMed ID: 33707236
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
11. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
[TBL] [Abstract][Full Text] [Related]
12. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
[TBL] [Abstract][Full Text] [Related]
13. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
14. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
[TBL] [Abstract][Full Text] [Related]
15. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.
Sheng W; LaFleur MW; Nguyen TH; Chen S; Chakravarthy A; Conway JR; Li Y; Chen H; Yang H; Hsu PH; Van Allen EM; Freeman GJ; De Carvalho DD; He HH; Sharpe AH; Shi Y
Cell; 2018 Jul; 174(3):549-563.e19. PubMed ID: 29937226
[TBL] [Abstract][Full Text] [Related]
16. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
17. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer.
Jotatsu T; Yagishita S; Tajima K; Takahashi F; Mogushi K; Hidayat M; Wirawan A; Ko R; Kanemaru R; Shimada N; Mitani K; Saito T; Takamochi K; Suzuki K; Kohsaka S; Kojima S; Mukae H; Yatera K; Takahashi K
Biochem Biophys Rep; 2017 Mar; 9():86-94. PubMed ID: 28955993
[TBL] [Abstract][Full Text] [Related]
18. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
[TBL] [Abstract][Full Text] [Related]
19. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I.
Yamamoto K; Venida A; Yano J; Biancur DE; Kakiuchi M; Gupta S; Sohn ASW; Mukhopadhyay S; Lin EY; Parker SJ; Banh RS; Paulo JA; Wen KW; Debnath J; Kim GE; Mancias JD; Fearon DT; Perera RM; Kimmelman AC
Nature; 2020 May; 581(7806):100-105. PubMed ID: 32376951
[TBL] [Abstract][Full Text] [Related]
20. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]